A randomized, placebo-controlled study of the effects of telcagepant on exercise time in patients with stable angina

Clinical Pharmacology and Therapeutics

Volumn 91, Issue 3, 2012, Pages 459-466

  Chaitman, B R ^a   Ho, A P ^b   Behm, M O ^b   Rowe, J F ^b   Palcza, J S ^b   Laethem, T ^c   Heirman, I ^c   Panebianco, D L ^b   Kobalava, Z ^d   Martsevich, S Y ^e   Free, A L ^f   Bittar, N ^g   Chrysant, S G ^h   Ho, T W ^b   Chodakewitz, J A ^b   Murphy, M G ^b   Blanchard, R L ^b  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MERCK RESEARCH LABORATORIES   (United States)

^c MSD   (Belgium)

^d PEOPLES FRIENDSHIP UNIVERSITY OF RUSSIA   (Russian Federation)

^e Center for Prophylactic Medicine   (Russian Federation)

^f Pinnacle Research Group   (United States)

^g Gemini Scientific   (United States)

^h UNIVERSITY OF OKLAHOMA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; TELCAGEPANT;

ADULT; AGED; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; FEMALE; FLUSHING; HEADACHE; HEART RATE; HEART VENTRICLE EXTRASYSTOLE; HUMAN; MAJOR CLINICAL STUDY; MALE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STABLE ANGINA PECTORIS; TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TREADMILL EXERCISE TIME;

ANGINA, STABLE; AZEPINES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; ELECTROCARDIOGRAPHY; EXERCISE TEST; FEMALE; HEART RATE; HUMANS; IMIDAZOLES; MALE; MIDDLE AGED; MIGRAINE DISORDERS; RECEPTORS, CALCITONIN GENE-RELATED PEPTIDE; VASODILATOR AGENTS;

EID: 84857232404     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2011.246     Document Type: Article

References (36)

1. Ferrari, M.D., Roon, K.I., Lipton, R.B. & Goadsby, P.J. Oral triptans (serotonin 5-HT(1B/1D) agonists) in acute migraine treatment: a meta-analysis of 53 trials. Lancet 358, 1668-1675 (2001). (Pubitemid 33124324)
2. Loder, E. Triptan therapy in migraine. N. Engl. J. Med. 363, 63-70 (2010).
3. Jamieson, D.G. The safety of triptans in the treatment of patients with migraine. Am. J. Med. 112, 135-140 (2002). (Pubitemid 34142545)
4. Dodick, D. et al.; Triptan Cardiovascular Safety Expert Panel. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache 44, 414-425 (2004). (Pubitemid 38685549)
5. Goadsby, P.J., Edvinsson, L. & Ekman, R. Release of vasoactive peptides in the extracerebral circulation of humans and the cat during activation of the trigeminovascular system. Ann. Neurol. 23, 193-196 (1988). (Pubitemid 18081459)
6. Paone, D.V. et al. Potent, orally bioavailable calcitonin gene-related peptide receptor antagonists for the treatment of migraine: discovery of N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl] -4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide (MK-0974). J. Med. Chem. 50, 5564-5567 (2007). (Pubitemid 350106011)
7. Salvatore, C.A. et al. Pharmacological characterization of MK-0974 [N-[(3R,6S)-6-(2,3-difluorophenyl)-2-oxo-1-(2,2,2-trifluoroethyl)azepan-3-yl] -4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide], a potent and orally active calcitonin gene-related peptide receptor antagonist for the treatment of migraine. J. Pharmacol. Exp. Ther. 324, 416-421 (2008). (Pubitemid 351185864)
8. Ho, T.W. et al.; MK-0974 Protocol 004 study group. Randomized controlled trial of an oral CGRP receptor antagonist, MK-0974, in acute treatment of migraine. Neurology 70, 1304-1312 (2008). (Pubitemid 351550355)
9. Ho, T.W. et al. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: a randomised, placebo-controlled, paralleltreatment trial. Lancet 372, 2115-2123 (2008).
10. Connor, K.M. et al. Randomized, controlled trial of telcagepant for the acute treatment of migraine. Neurology 73, 970-977 (2009).
11. Connor, K.M. et al. Long-term tolerability of telcagepant for acute treatment of migraine in a randomized trial. Headache 51, 73-84 (2011).
12. Han, T.H. et al. Single-and multiple-dose pharmacokinetics and tolerability of telcagepant, an oral calcitonin gene-related peptide receptor antagonist, in adults. J. Clin. Pharmacol. 50, 1367-1376 (2010).
13. Lynch, J.J. Jr, Regan, C.P., Edvinsson, L., Hargreaves, R.J. & Kane, S.A. Comparison of the vasoconstrictor effects of the calcitonin gene-related peptide receptor antagonist telcagepant (MK-0974) and zolmitriptan in human isolated coronary arteries. J. Cardiovasc. Pharmacol. 55, 518-521 (2010).
14. Edvinsson, L. et al. Effect of the calcitonin gene-related peptide (CGRP) receptor antagonist telcagepant in human cranial arteries. Cephalalgia 30, 1233-1240 (2010).
15. Blanchard, R. et al. High dose telcagepant has no effect on 24-hr ambulatory blood pressure or heart rate in healthy volunteers. Headache 50 (suppl. 1), S35-S36 (2010).
16. Uren, N.G., Seydoux, C. & Davies, G.J. Effect of intravenous calcitonin gene related peptide on ischaemia threshold and coronary stenosis severity in humans. Cardiovasc. Res. 27, 1477-1481 (1993). (Pubitemid 23265069)
17. Mair, J., Lechleitner, P., Lgle, T., Wiedermann, C., Dienstl, F. & Saria, A. Plasma CGRP in acute myocardial infarction. Lancet 335, 168 (1990). (Pubitemid 20032764)
18. Burley, D.S., Hamid, S.A. & Baxter, G.F. Cardioprotective actions of peptide hormones in myocardial ischemia. Heart Fail. Rev. 12, 279-291 (2007). (Pubitemid 350176701)
19. Kinoshita, M. & Sakai, K. Pharmacology and therapeutic effects of nicorandil. Cardiovasc. Drugs Ther. 4, 1075-1088 (1990). (Pubitemid 20330472)
20. Thadani, U. et al. Double-blind, dose-response, placebo-controlled multicenter study of nisoldipine. A new second-generation calcium channel blocker in angina pectoris. Circulation 84, 2398-2408 (1991).
21. Chrysant, S.G. et al. Efficacy and safety of extended-release isosorbide mononitrate for stable effort angina pectoris. Am. J. Cardiol. 72, 1249-1256 (1993). (Pubitemid 23357785)
22. Chaitman, B.R. et al. Asymptomatic Cardiac Ischemia Pilot (AC IP) study: impact of anti-ischemia therapy on 12-week rest electrocardiogram and exercise test outcomes. The AC IP Investigators. J. Am. Coll. Cardiol. 26, 585-593 (1995).
23. Lewis, B.S. Efficacy and safety of nisoldipine coat core in the management of angina pectoris, systemic hypertension, and ischemic ventricular dysfunction. Am. J. Cardiol. 75, 46E-53E (1995).
24. Fragasso, G. et al. Nitric-oxide mediated effects of transdermal capsaicin patches on the ischemic threshold in patients with stable coronary disease. J. Cardiovasc. Pharmacol. 44, 340-347 (2004). (Pubitemid 39129453)
25. Chaitman, B.R. et al. Antianginal efficacy of omapatrilat in patients with chronic angina pectoris. Am. J. Cardiol. 95, 1283-1289 (2005). (Pubitemid 40719857)
26. Sen, N. et al. Nebivolol therapy improves endothelial function and increases exercise tolerance in patients with cardiac syndrome X. Anadolu Kardiyol. Derg. 9, 371-379 (2009).
27. Tardif, J.C., Ponikowski, P. & Kahan, T.; ASSOCIATE Study Investigators. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial. Eur. Heart J. 30, 540-548 (2009).
28. Thadani, U. et al. The effect of vardenafil, a potent and highly selective phosphodiesterase-5 inhibitor for the treatment of erectile dysfunction, on the cardiovascular response to exercise in patients with coronary artery disease. J. Am. Coll. Cardiol. 40, 2006-2012 (2002). (Pubitemid 35425369)
29. Glasser, S.P., Gana, T.J., Pascual, L.G. & Albert, K.S. Efficacy and safety of a oncedaily graded-release diltiazem formulation dosed at bedtime compared to placebo and to morning dosing in chronic stable angina pectoris. Am. Heart J. 149, e1-e9 (2005).
30. Patterson, D. et al. The effect of tadalafil on the time to exercise-induced myocardial ischaemia in subjects with coronary artery disease. Br. J. Clin. Pharmacol. 60, 459-468 (2005). (Pubitemid 41532445)
31. Fox, K.M. et al.; CA ESAR I (Clinical American and European Studies of Angina and Revascularization) investigators. Sildenafil citrate does not reduce exercise tolerance in men with erectile dysfunction and chronic stable angina. Eur. Heart J. 24, 2206-2212 (2003). (Pubitemid 37522673)
32. Sinclair, S.R. et al. Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974). Br. J. Clin. Pharmacol. 69, 15-22 (2010).
33. Mark, D.B. et al. Prognostic value of a treadmill exercise score in outpatients with suspected coronary artery disease. N. Engl. J. Med. 325, 849-853 (1991).
34. Caralis, D.G. et al. Application of computerized exercise ECG digitization. Interpretation in large clinical trials. J. Electrocardiol. 25, 101-110 (1992).
35. Jones, B. & Kenward, M.G. Design and Analysis of Cross Over Trials. 2nd edn, 13-53. (Chapman and Hall/CRC, 2003).
36. Chaitman, B.R. et al.; Combination Assessment of Ranolazine In Stable Angina (CA RISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA 291, 309-316 (2004). (Pubitemid 38101603)